Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 14;45(7):637-644.
doi: 10.3760/cma.j.cn121090-20240611-00218.

[Chinese consensus on autologous stem cell transplantation for adult acute leukemia (2024)]

[Article in Chinese]
Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association

[Chinese consensus on autologous stem cell transplantation for adult acute leukemia (2024)]

[Article in Chinese]
Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Autologous stem cell transplantation (ASCT) emerges as a therapeutic strategy following remission in adult acute leukemia (AL). It offers advantages over allogeneic hematopoietic stem cell transplantation (allo-HSCT), including independence from donor availability, absence of graft-versus-host disease (GVHD), and a reduced risk of transplant-related mortality. Furthermore, when juxtaposed with the extended regimens of consolidation chemotherapy, ASCT stands out by markedly abbreviating treatment duration, alleviating the economic strain on patients, and enhancing their overall quality of life. Despite these benefits, the adoption of ASCT among adult AL patients in China remains disproportionately low. To enhance clinical physicians' understanding of the role and position of ASCT in AL management and to improve the clinical efficacy of ASCT, it is urgent to establish a consensus among experts on ASCT for adult acute leukemia in our nation.

自体造血干细胞移植（autologous stem cell transplantation，ASCT）是成人急性白血病（AL）缓解后治疗的方法之一。与异基因造血干细胞移植（allo-HSCT）相比，ASCT具有不受供者限制、不发生移植物抗宿主病（GVHD）、移植相关死亡率低等优点；与多疗程的巩固化疗相比，ASCT能显著缩短治疗时间、减轻患者经济负担，提升患者生活质量。但目前，我国成人AL患者接受ASCT数量较少。为提高临床医师对ASCT在成人AL治疗中作用和地位的认识，提高ASCT临床疗效，亟待制定我国成人急性白血病自体造血干细胞移植专家共识。.

PubMed Disclaimer

Figures

图1
图1. 成人急性髓系白血病（AML）患者自体造血干细胞移植（auto-HSCT）的适应证选择–,–
注 APL：急性早幼粒细胞白血病；CR1、CR2：第1、2次完全缓解；MRD：微小残留病
图2
图2. 成人急性淋巴细胞白血病（ALL）自体造血干细胞移植（auto-HSCT）的适应证选择,–
注 Ph：费城染色体；CR1：第1次完全缓解；MRD：微小残留病
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Heini AD, Berger MD, Seipel K, et al. Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years[J] Leuk Res. 2017;28-34 doi: 10.1016/j.leukres.2016.12.001. - DOI - PubMed
    1. Yu S, Fan Z, Ma L, et al. Association between measurable residual disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes[J] JAMA Netw Open. 2021;4(7):e2115991. doi: 10.1001/jamanetworkopen.2021.15991. - DOI - PMC - PubMed
    1. Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia[J] Blood. 2019;134(12):935–945. doi: 10.1182/blood.2018886960. - DOI - PubMed
    1. Yao J, Zhang G, Liang C, et al. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission[J] Leuk Res. 2017;55:97–104. doi: 10.1016/j.leukres.2017.01.026. - DOI - PubMed
    1. Yu S, Lin T, Nie D, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes[J] Blood Cancer J. 2021;11(12):195. doi: 10.1038/s41408-021-00591-4. - DOI - PMC - PubMed

Publication types